SERF VT Study Presented as Part of HRS 2020 Science Late-Breaking Clinical Trial Sessions

Results Suggest Highly Effective Method to Treat Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death

Thermedical® announced results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate® catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today.

Called the Saline Enhanced Radiofrequency (SERF) VT Ablation EFS, preliminary results were presented by the study’s Lead Investigator, Douglas L. Packer, M.D., professor of medicine at the Mayo Clinic, on Heart Rhythm 365, the society’s digital education platform.

“Our data from the First-in-Human EFS suggest a highly feasible approach to treating patients with recurrent VT that is resistant to other treatments,” said Dr. Packer.

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Durablate catheter to treat VT, a leading cause of sudden cardiac death worldwide. The target study population consists of patients who have failed all current forms of treatment including Implantable Cardioverter Defibrillators (ICDs), medical therapy and other forms of ablation therapy. The Durablate catheter uses a needle electrode to deliver heated, degassed saline and radiofrequency energy into the tissue to more effectively treat the tissue causing the VT than a standard, conventional ablation catheter.

Early feasibility results of 32 patients treated at six centers in the U.S. and Canada indicate that the SERF Durablate catheter is highly effective at eliminating clinical VT in patients with an acute procedural success rate of 100 percent and shows acceptable initial safety.

Five-month follow-up data demonstrate that more than half of the patients had no recurrent VT and more than 60 percent of the patients had their VT reduced by 90 percent or more. In contrast, for the six months prior to ablation, patients had a median of 40 ICD treatments (shock or antitachycardia pacing), which can significantly reduce quality of life. The Durablate catheter was used to deliver an average of 10 lesions per case and the average total procedure time was four hours and 42 minutes, which is significantly shorter than typical conventional RF procedures for patients of this nature.

“We are extremely encouraged by these early results as it puts us one step closer to advancing treatment that can reduce or eliminate VT episodes in patients,” said Michael Curley, Ph.D., FHRS, co-founder and chief executive officer of Thermedical. “Moreover, a successful and effective method to treat VT that is drastically shorter and more effective than current ablation procedures would improve quality of life considerably for people who develop, or who are at high risk of developing VT every year.

“We believe our SERF ablation therapy may serve as an adjunct to, or as a possible alternative to ICDs, and equally as important, it may be a low-cost alternative for treating VT, saving the U.S. healthcare system substantially in costs associated with current VT treatment,” added Dr. Curley.

The SERF VT EFS is underway in the U.S. at Mayo Clinic, Loyola University Medical Center, and Vanderbilt University Medical Center, and in Canada at Southlake Regional Health Centre, Montreal Heart Institute and Quebec Heart and Lung Institute.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version